Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...

A bill under consideration in the legislature would position Iowa to immediately allow prescriptions of a synthetic version ...

Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a ...

Laromestrocel (Lomecel-B™) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disease ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Q4 2024 Earnings Call Transcript March 20, 2025 Cognition Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks ...

Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release ...

Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017 ... Green learned about a clinical trial at Mass General for an experimental drug — QALSODY ...

An informed consent form tells you the purpose ... Clinical research is overseen by the FDA to ensure trials are designed, conducted, analyzed, and reported according to federal law and good clinical ...

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric ...